Threonine and tyrosine kinase ( TTK ) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting
Histopathology · 2025
DOI: 10.1111/his.15399 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Abrar Ashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Medicine, Leeds Institute of Medical Research, St James's University Hospital, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Protein Serine-Threonine Kinases, Protein-Tyrosine Kinases, Cell Cycle Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Birmingham CU-UK grant number, Ministry of Education - Kingdom of Saudi Arabia.
Abstract (Originalsprache)
Aims
Threonine and tyrosine kinase (TTK) is up‐regulated in triple‐negative breast cancer (TNBC), yet its expression in patients undergoing neoadjuvant chemotherapy (NACT) remains unexplored. This investigation aims to assess TTK protein expression in treatment‐naïve pre‐treatment cores and paired pre‐ and post‐NACT breast cancer (BC) cohorts, as well as its correlation with microcephaly 1 (MCPH1) protein expression. Methods and results Transcriptomic data were sourced from the Gene Expression Omnibus microarray database for mRNA expression analysis. TTK protein expression was evaluated using immunohistochemistry staining, employing receiver operating characteristic curve analysis to determine an optimal TTK expression cut‐off point. The association between TTK expression, clinicopathological parameters and survival outcomes was examined. Additionally, MCPH1 protein expression was assessed in a pilot study. Analysis revealed a significantly elevated TTK mRNA expression in BC tissue compared to normal breast tissue, with high TTK mRNA levels predicting reduced overall survival. Notably, TTK protein expression increased significantly post‐NACT in a paired cohort. Conversely, decreased TTK protein expression pre‐NACT was correlated with improved overall survival.
Conclusions
High TTK and low MCPH1 protein expression was significantly correlated, highlighting TTK's potential as a biomarker for BC and a therapeutic target for MCPH1‐deficient cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Medicine, Leeds Institute of Medical Research, St James's University Hospital, University of Leeds, Leeds, UK.
- Histopathology, St James's Institute for Oncology, St James's University Hospital, Leeds, UK.
- Histopathology and Cancer Sciences, Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK.
ORCID-Profile: Abrar Ashi, Aeshah A Awaji, Jacquelyn Bond, Colin A Johnson, Abeer M Shaaban, Sandra M Bell
Förderung
- Birmingham CU-UK grant number
- Ministry of Education - Kingdom of Saudi Arabia
Zitieren
APA
Ashi, A., Awaji, A. A., Bond, J., Johnson, C. A., Shaaban, A. M., & Bell, S. M. (2025). Threonine and tyrosine kinase ( TTK ) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting. Histopathology. https://doi.org/10.1111/his.15399
Vancouver
Ashi A, Awaji AA, Bond J, Johnson CA, Shaaban AM, Bell SM. Threonine and tyrosine kinase ( TTK ) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting. Histopathology. 2025. doi:10.1111/his.15399
BibTeX
@article{Ashi2025,
author = {Ashi, Abrar and Awaji, Aeshah A and Bond, Jacquelyn and Johnson, Colin A and Shaaban, Abeer M and Bell, Sandra M},
title = {Threonine and tyrosine kinase ( TTK ) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting},
journal = {Histopathology},
year = {2025},
doi = {10.1111/his.15399}
}
EUVIMED